2014 Clinical Trials Data Epilepsy 
Cannabis Law Report
JANUARY 10, 2022
This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.
Canna Care Docs
DECEMBER 16, 2020
The evidence of its effectiveness is clear, as clinical trials have shown a significant reduction in pain for patients suffering with neuropathic pain from multiple sclerosis, pain from rheumatoid arthritis, cancer pain, HIV or complex regional pain syndrome, headaches and menstrual pain, among other potential uses. Chronic pain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 24, 2019
T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.
Cannabis Law Report
JUNE 1, 2021
Director of Medical Affairs and a Product Development Team lead at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based product approved by the FDA to treat rare forms of epilepsy.
SMPL
MAY 26, 2020
“Within a couple of years, they figured out a 1:1 combination of a high-THC chemovar and a high-CBD chemovar presented the greatest latitude of effects and prevention of side effects,” said Dr. Ethan Russo, who worked with GW Pharmaceuticals from 1998 to 2014. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex.
Cannabis Law Report
NOVEMBER 24, 2021
At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Data collection. Palliative care indications.
Green Relief
MAY 13, 2018
A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.
Expert insights. Personalized for you.
52 
Let's personalize your content